61/100B51.365
USD
-0.33
(-0.64%)
Market Closed
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate 0.23Revenue estimate 1.25B
Q4 FY2026 · Earnings report
EPS estimate 0.23Revenue estimate 1.25B
If you had invested in Genmab A/S ADS ago, it would be worth $2,924 today, against $4,081 in SPY and $6,291 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
61/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation2.5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders10
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Genmab A key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Blend stock · 1.5/10Growth 1.4 · Value 1.5
- Day range
- 50.720 – 51.560
- 52-week range
- 23.620 – 59.970
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 31.67B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 43.27
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 2.30
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 1.19
- EPS growth forecast (FY2026)
- -19.4%
- Volume
- 177,371
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.65
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 53.8/100Environment 36 · Social 66 · Governance 60
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jan van de Winkel
- Employees
- 3K
- Website
- genmab.com
- IPO date
- 1 Jun 2009
Genmab A earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
0.23 USD
Revenue estimate
1.25B USD
Last quarter · Q3 FY2026
EPS0.56Beat +55.6%Revenue1.19BMissed -0.9%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 0.20 | — | — | +126.00% | 1.11B | — | — | +24.26% | |
| Q4 FY2026 | 0.23 | — | — | +360.00% | 1.25B | — | — | +18.37% | |
| Q3 FY2026 | 0.36 | 0.56 | +55.56% | -13.85% | 1.20B | 1.19B | -0.92% | +16.14% | |
| Q2 FY2026 | 0.37 | 0.54 | +45.95% | 0.00% | 1.12B | 1.16B | +3.46% | +24.89% | |
| Q1 FY2026 | 0.15 | 0.09 | -42.00% | -71.94% | 905.77M | 896.00M | -1.08% | +23.42% | |
| Q4 FY2025 | 0.46 | 0.05 | -89.13% | -91.23% | 1.07B | 1.06B | -0.76% | +18.11% | |
| Q3 FY2025 | 0.48 | 0.65 | +35.42% | +124.14% | 1.01B | 1.02B | +1.08% | +25.37% | |
| Q2 FY2025 | 0.39 | 0.54 | +38.46% | +145.45% | 952.56M | 924.81M | -2.91% | +17.13% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 2.70 | — | — | +66.17% | 6.90B | — | — | +27.45% |
| FY2027 | 1.63 | — | — | +30.17% | 5.41B | — | — | +20.99% |
| FY2026 | 1.25 | — | — | -19.43% | 4.47B | — | — | +19.94% |
| FY2025 | 1.72 | 1.55 | -10.12% | +25.00% | 3.71B | 3.73B | +0.66% | +20.40% |
| FY2024 | 1.20 | 1.24 | +3.13% | +5.08% | 3.00B | 3.10B | +3.42% | +30.52% |
| FY2023 | 1.10 | 1.18 | +6.91% | +0.85% | 2.39B | 2.37B | -0.47% | +15.82% |
| FY2022 | 1.43 | 1.17 | -18.10% | +60.27% | 2.03B | 2.05B | +0.88% | +54.85% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Genmab A analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
50.83 USD
-1.04%
Analysts' 1-year price targets range from 40.00 to 70.00, with an average of 50.83.
Past year
1-year forecast
Strong sellStrong buy
Strong buy
6 ratings
| Buy | 5 | |
| Hold | 1 | |
| Sell | 0 |
12-month price target
| Highest target | 70.00 |
| Average target | 50.83 |
| Lowest target | 40.00 |
| Current price | 51.37 |
Genmab A valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 43.27
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 41.13
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 7.37
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 5.00
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 28.97
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
31.67B USD
+
Total debt
5.20B USD
−
Cash and short-term investments
1.86B USD
=
Enterprise value
35.01B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Genmab A against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Revolution Medicines, United Therapeutics, Incyte, Insmed, Alnylam Pharmaceuticals, and Exelixis, the US Biotechnology companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median43.32.347.0
- Gross marginLowest in 5 years91.7%91.7%100.0%Against its peers: 4 of 7Peers' median 90.3%
- Operating marginAt its median33.6%31.1%43.2%Against its peers: 3 of 7Peers' median 19.8%
- Net marginLowest in 5 years25.9%25.9%37.6%Against its peers: 3 of 7Peers' median 16.7%
- Return on equityAt its median16.5%13.3%21.4%Against its peers: 5 of 7Peers' median 21.9%
- Free cash flow marginAt its median30.9%23.5%42.5%Against its peers: 3 of 7Peers' median 19.4%
- Revenue growthLowest in 5 years-82.7%-82.7%72.3%Against its peers: 7 of 7Peers' median 15.9%
- EPS growthLowest in 5 years-87.3%-87.3%84.4%Against its peers: 4 of 4Peers' median 58.0%
- Debt to EBITDAHighest in 5 years4.06×0.08×4.06×Against its peers: 5 of 5Peers' median 0.11×
- Current ratioLowest in 5 years2.022.0215.48Against its peers: 7 of 7Peers' median 3.69
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Genmab A growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 4.30B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 729.10M USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 92.60%
- Operating margin
- 30.63%
- Net margin
- 16.97%
Revenue / Net income
Revenue Net income Net margin
How Genmab A makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Revenue3.72B 100.0%
Cost of revenue309.24M 8.3%
Gross profit3.41B 91.7%
Research and development1.56B 41.9%
Selling and administration602.47M 16.2%
Operating income1.25B 33.6%
Tax241.19M 6.5%
Other expense46.04M 1.2%
Net income963.76M 25.9%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Genmab A financial health
- Cash and short-term investments
- 1.86B USD
- Total debt
- 5.20B USD
- Net cash
- -3.34B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 842.34M USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 2.45
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.82
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 5 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 21.42
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Genmab A ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 16.70%
- Institutional holders
- 307 (+26)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 95.53%
Who owns the shares
Institutions 16.7% Others 83.3%
As of 30 Jun 2026
Shares free to trade
Free float 589.06M shares ·95.5% Closely held 27.54M shares ·4.5%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: Genmab A/S ADS
Sector: Healthcare
Industry: Biotechnology
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.